NEWS ABOUT THE CURE

Creating Good Cancer Research

In previous articles we’ve discussed key fundamentals of The Cure Starts Now grant funding process. And while this helps to perfect what we fund, how exactly does the Medical Advisory Council of The Cure Starts Now keep creating and finding good projects? The first thing to understand is that The Cure Starts Now is the “un-charity”. Rather than to simply assume the mistakes of the past, we believe the model of cancer research must be revolutionized. We just can fund the same projects others fund

How The Cure Starts Now Funds Better Research

In just 12 short years, The Cure Starts Now has already been at the forefront of many of the world's most innovative cancer fighting strategies.  Why? How does a small charity with a limited focus match the impact of some of the world’s largest charities?  The answer is strategy. Funding cancer research is just about how you fund as much as what you fund.  And when you have limited funds, the last thing you want is to waste critical dollars.  That's why every dollar spent by The Cure Starts Now

The Cure Starts Now and Partners Renew Oncoceutics Expanded Access of ONC201

In partnership with xCures, Cancer Commons and the Musella Foundation, The Cure Starts Now is pleased to announce a renewal of $100,000 for the Oncoceutics Expanded access of ONC201, bringing the total contribution by The Cure Starts Now to over $267,000. Part of this program is an intermediate size Expanded access protocol for ONC201 in patients with H3 K27M-mutant glioma entitled “ONC018: Expanded access to ONC201 for Patients with H3 K27M-mutant and/or Midline High Grade Gliomas” that was re

Dr. Mark Kieran Discusses the DIPG/DMG Symposium and the Efforts of The Cure Starts Now in Facilitating Research

Dr. Mark Kieran, Lead for Pediatrics at Bristol-Myers Squibb About Understanding and Collaboration “I’ve been coming to this symposium now for a while and the most important aspect is to really broaden the understanding as to get the community to work together. DIPG is a relatively rare tumor, it affects a small number of patients around the world. Bringing all of those investigators into one place and to a unified atmosphere where they can really begin to see not just what they’re doing but

Dr. Michelle Monje Discusses Overall Progress in DIPG and DMG Research and The Cure Starts Now's Support of Her Efforts

Dr. Michelle Monje, Pediatric Neuro-oncologist, Stanford University School of Medicine “When I first came to the DIPG field after taking care of a child with DIPG in medical school I realized that I needed to work on this scientifically and take care of these children in the clinic. At that time we knew absolutely nothing about the disease. We didn’t have any experimental model systems to study it, we didn’t know what mutations were driving it, we didn’t have any idea what potential therapeut

Dr. David Ziegler Discusses the Value of Collaboration at the DIP/DMG Symposium and The Cure STarts Now Foundation's Emphasis on Innovative Research

Dr. David Ziegler, Associate Professor at the Children’s Cancer Institute and at Sydney Children’s Hospital “The DIPG|DMG Symposium has been absolutely incredible collaborative affair bringing together the best and the brightest researchers and doctors and scientists from around the world. Together with parents and fundraisers and stakeholders to put all our minds together to come up with new ideas to look at what’s been achieved in the last couple of years, to work out what’s been done in th

Dr. Chris Jones Talks About the Value of Collaboration and the Funding Efforts of The Cure Starts Now

Dr. Chris Jones, The Institute of Cancer Research, at the Royal Marsden Hospital in London. “Bringing together these kind of researchers and families at this sort of meeting, this is really probably my favorite meeting that I go to: it's really inspiring to see all the other researchers and clinicians, hearing about what they're doing, look for obvious areas that we could work together, but also being in the same room as the families, and the foundations, hearing their stories.” About the Val

Dr. Nick Gottardo Discusses Recent Advances in Research of DIPG and the Success of the DIPG/DMG Symposium

Dr. Nick Gottardo, Head of Pediatric Oncology Hematology, Perth Children's Hospital and Co-Lead of Brain Tumor Research at the Telethon Kids Institute. The Cure Starts Now Medical Advisory Council Member “We now know the disease much better, we understand it much better. And if you understand something then you can exploit vulnerabilities in it.” About the DIPG | DMG Symposium “The meeting that occurs every two years is a meeting that brings all the best minds working in DIPG regardless of

Dr. Michelle Monje Discusses Recent Advances From a Project Funded By The Cure Starts Now on the Cellular Communication of DIPG

"DIPG very, very closely resembles a normal glial precursor cell, called an oligodendrocytes precursor cell and that cell type, is the only cell type - the only glial cell type - that actually forms synapses with neurons. We've known this for the last twenty years although the field is still trying very hard to understand what it is these neuron-to-glial synapses do in the healthy brain. When we thought that perhaps DIPG cells and other high-grade glioma cells might be similarly forming synap

Local Giving Tuesday Event Goes International

The Cure Starts Now breaks records raising over $273,000 in online telethon Cincinnati, OH | December 3, 2019 — Cincinnati-based and founded charity, The Cure Starts Now Foundation, held its second annual Giving Tuesday online telethon on Tuesday, December 3rd.  Initiated by the 44 chapters of The Cure Starts Now in 3 countries, 2019 also hosted about 60 local participants at its Cincinnati based headquarters as part of its “100 Families Strong” event.  In total over 154 families and their child